Overview

Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer

Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus paclitaxel and gemcitabine in treating patients with platinum-resistant recurrent ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Southern California
Collaborator:
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Dexamethasone
Gemcitabine
Paclitaxel